Evidence map›Paper›PMID 27699176›Full record

ArticleBioMed research international2016

Effects of Bufei Yishen Granules Combined with Acupoint Sticking Therapy on Pulmonary Surfactant Proteins in Chronic Obstructive Pulmonary Disease Rats.

Yange Tian, Jiansheng Li, Ya Li, Yuqiong Dong, Fengjia Yao, Jing Mao, Linlin Li, Lili Wang, Shan Luo, Minghang Wang

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yange TianCollaborative Innovation Center for Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province, Zhengzhou, Henan 450046, China; Institute for Geriatrics, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450046, China.
Jiansheng LiCollaborative Innovation Center for Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province, Zhengzhou, Henan 450046, China; Institute for Geriatrics, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450046, China; Institute for Respiratory Diseases, The First Affiliated Hospital, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450008, China.ORCID 0000-0002-2714-9353
Ya LiCollaborative Innovation Center for Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province, Zhengzhou, Henan 450046, China; Institute for Geriatrics, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450046, China; Central Laboratory and Respiratory Pharmacological Laboratory of Chinese Medicine, The First Affiliated Hospital, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450008, China.
Yuqiong DongCollaborative Innovation Center for Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province, Zhengzhou, Henan 450046, China; Institute for Geriatrics, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450046, China.
Fengjia YaoCollaborative Innovation Center for Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province, Zhengzhou, Henan 450046, China; Institute for Geriatrics, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450046, China.
Jing MaoCollaborative Innovation Center for Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province, Zhengzhou, Henan 450046, China; Institute for Geriatrics, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450046, China.
Linlin LiCollaborative Innovation Center for Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province, Zhengzhou, Henan 450046, China; Institute for Geriatrics, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450046, China.
Lili WangCollaborative Innovation Center for Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province, Zhengzhou, Henan 450046, China; Institute for Geriatrics, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450046, China.
Shan LuoCollaborative Innovation Center for Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province, Zhengzhou, Henan 450046, China; Institute for Geriatrics, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450046, China.
Minghang WangCollaborative Innovation Center for Respiratory Disease Diagnosis and Treatment & Chinese Medicine Development of Henan Province, Zhengzhou, Henan 450046, China; Institute for Geriatrics, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450046, China; Institute for Respiratory Diseases, The First Affiliated Hospital, Henan University of Traditional Chinese Medicine, Zhengzhou, Henan 450008, China.
Henan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our previous studies have demonstrated the beneficial effects of Bufei Yishen granules combined with acupoint sticking therapy (the integrated therapy) in chronic obstructive pulmonary disease (COPD), but the underlying mechanism remains unclear. Dysfunction of pulmonary surfactant proteins (SPs, including SP-A, SP-B, SP-C, and SP-D) may be included in pathophysiology of COPD. This study aimed to explore the mechanism of the integrated therapy on SPs. COPD rat models were established. The treatment groups received Bufei Yishen granules or acupoint sticking or their combination. Using aminophylline as a positive control drug. The levels of SPs in serum, BALF, and lung were measured. The results showed that the integrated therapy markedly reduced the levels of SPs in serum and increased these indicators in the lung. The integrated therapy was better than aminophylline in reducing the levels of SPs and was better than Bufei Yishen granules in reducing SP-A, SP-C, and SP-D in serum. The integrated therapy was better than aminophylline and Bufei Yishen granules in increasing SP-A, SP-B, and SP-D mRNA in the lung. SP-A and SP-D in BALF were positively correlated with PEF and EF50. The levels of SPs are associated with airway limitation. The beneficial effects of the integrated therapy may be involved in regulating pulmonary surfactant proteins.

Indexed as

Acupuncture PointsAcupuncture TherapyAnimalsBronchoalveolar Lavage FluidCombined Modality TherapyDrugs, Chinese HerbalFemaleLungMalePulmonary Disease, Chronic ObstructivePulmonary Surfactant-Associated ProteinsRatsRats, Sprague-DawleyRespiratory Function TestsRNA, MessengerBu-Fei-Yi-ShenDrugs, Chinese HerbalPulmonary Surfactant-Associated ProteinsRNA, Messenger

Identifiers

PMID27699176
PMCPMC5028822
OpenAlexW2507756868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.